Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (14391)	1/12/2006 10:43:11 AM
From: ACAN	Read Replies (1) \| Respond to of 23958

Sergio; [RMTI] appropos. Rockwell Medical Technologies, Inc. Receives $13 Million Supply Order Thursday January 12, 10:30 am ET WIXOM, Mich., Jan. 12 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI - News), a leading, innovative dialysis products manufacturer serving the healthcare industry reported today that it has received a $13,015,860 purchase order for dialysis concentrate and supplies. The $13,015,860 order is for dialysis business secured in Latin America. The Company anticipates fulfilling the entire purchase order during the 2006 calendar year. ADVERTISEMENT Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We are pleased to have secured this substantial supply order and we will continue to work to secure more business going forward. We anticipate that this order will have a favorable impact on both our sales and earnings during 2006." On November 8, 2005, Rockwell reported that revenues for the first nine- months of 2005 increased 61% to $21,238,803 compared to the first nine months of 2004, while net profit increased 75% to $350,848 and earnings per share increased to $.04 over the same period. Rockwell Medical Technologies, Inc. is an innovative leader in manufacturing, marketing, and delivering high-quality dialysis solutions, powders, and ancillary products that improve the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work properly and suffer from chronic kidney failure, a condition also known as end stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased approximately 6%-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items. Visit Rockwell's website at rockwellmed.com for more information. Certain statements in this press release with respect to Rockwell's anticipated sales revenue and earnings constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, any breach of a contract by a major customer, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties. -------------------------------------------------------------------------------- Source: Rockwell Medical Technologies, Inc. Watch that puppy move. Allan

To: Sergio H who wrote (14391)	1/27/2006 3:24:47 PM
From: manny t	Read Replies (1) \| Respond to of 23958

RMTI, It looks like Perkins Capital Management might have gotten some of the warrants that expired yesterday (or shorted into the warrants to bring the price down and then bought more in the open market). It is also interesting that Perkins owned 5.13% of RMTI as of 9/30/05 as per Yahoo Finance,so they must have sold between then and their recent buys for them to have to file their new report. finance.yahoo.com This could be the bottom which Perkins created. Manny